Analysis of Health Status of Сomorbid Adult COVID-19 Patients Hospitalised in Second Wave of SARS-CoV-2 Infection
ACTIV-2
1 other identifier
observational
2,968
1 country
1
Brief Summary
Comparison of COVID-19 disease course in hospitalized patients infected by SARS-CoV-2 in first and second waves of the novel coronavirus infection
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Oct 2020
Shorter than P25 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
October 1, 2020
CompletedFirst Submitted
Initial submission to the registry
January 13, 2021
CompletedFirst Posted
Study publicly available on registry
January 14, 2021
CompletedPrimary Completion
Last participant's last visit for primary outcome
March 30, 2021
CompletedStudy Completion
Last participant's last visit for all outcomes
May 30, 2021
CompletedSeptember 8, 2023
September 1, 2023
6 months
January 13, 2021
September 6, 2023
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
death
death for any reason
4 weeks
Secondary Outcomes (6)
Number of cases of Acute Kidney Injury depending on Coexisting Conditions
4 weeks
Number of cases of Myocarditis and Acute Coronary Events depending on Coexisting Conditions
4 weeks
Number of cases of Cytokine Storm depending on Coexisting Conditions
4 weeks
Number of thrombotic and thromboembolic complications of COVID-19 depending on Coexisting Conditions
4 weeks
Decline in GFR excluding Acute Kidney Injury by the time of discharge depending on Coexisting Conditions
4 weeks
- +1 more secondary outcomes
Eligibility Criteria
Anonymized male and female patients over the age of 18 hospitalised since October, 1st, 2020
You may qualify if:
- Suspected or confirmed COVID-19 (according to results of swab-test, antibody test, computed tomography or radiography image)
You may not qualify if:
- Unwillingness to participate in the study;
- Age under 18.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Eurasian Association of Therapists
Moscow, 101000, Russia
Related Links
- design of observational studies "Analysis of Chronic Non-infectious Diseases Dynamics After COVID-19 Infection in Adult Patients" and "Analysis of Health Status of Сomorbid Adult COVID-19 Patients Hospitalised in Second Wave of SARS-CoV-2 Infection"
- Lipid profile in hospitalized patients with COVID-19 depending on the outcome of its acute phase: data from the international registry "Dynamics analysis of comorbidities in SARS-CoV-2 infection survivors"
- Impact of Kidney Damage on the Course and Prognosis of COVID-19 Infection According to the International Registry "Analysis of Chronic Non-Infectious Diseases Dynamics After Covid-19 Infection in Adult Patients"
- The impact of carbohydrate metabolism disorders on the early and long-term clinical outcomes of patients with COVID-19 according to the AKTIV and AKTIV 2 registries.
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- STUDY DIRECTOR
Grigoriy Arutyunov, MD, PhD
Eurasian Association of Therapists
- STUDY CHAIR
Ekaterina Tarlovskaya, MD, PhD
Eurasian Association of Therapists
- PRINCIPAL INVESTIGATOR
Aleksander Arutyunov, MD, PhD
Eurasian Association of Therapists
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- OTHER
- Target Duration
- 4 Weeks
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Eurasian Association of Therapists
Study Record Dates
First Submitted
January 13, 2021
First Posted
January 14, 2021
Study Start
October 1, 2020
Primary Completion
March 30, 2021
Study Completion
May 30, 2021
Last Updated
September 8, 2023
Record last verified: 2023-09
Data Sharing
- IPD Sharing
- Will not share